key: cord-0878149-24764w8w
authors: Cove, Matthew E.; Pinsky, Michael R.
title: Rethinking Alveolar Ventilation and CO(2) Removal
date: 2021-02-01
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.202008-3306ed
sha: 491ef336f8c7c0865d427985ea4f6992c52d317f
doc_id: 878149
cord_uid: 24764w8w

nan

I recall my mentor and coauthor (M.R.P.) sharing a personal story from the 1970s. He had heard that Drs. Ted Kolobow and Luciano Gattinoni had performed an extracorporeal carbon dioxide removal (ECCO 2 R) experiment in sheep. They showed that pulmonary ventilation progressively decreased until breathing ceased as CO 2 removal with ECCO 2 R approached metabolic CO 2 production (1). This innovative work confirmed important principles of respiratory drive and was groundbreaking enough for my mentor (a young man at the time) to travel from Johns Hopkins in Baltimore to the National Heart Institute in Bethesda and see it for himself. Fast forward to the 21st century, and it is hard to imagine my fellows showing such avid interest in CO 2 . In fact, clinicians today appear to have a greater interest in oxygen physiology. This state of affairs is entirely understandable; noninvasive bedside monitoring provides us with regular information on oxygen status, whereas acquisition of information on CO 2 status generally demands more commitment.

The current pandemic has exposed the impact of our knowledge imbalance in this regard, because the mysterious "happy hypoxia" reported in patients with coronavirus disease (COVID-19) (2) is not nearly so mysterious when one considers the role of CO 2 in determining respiratory drive (3). Along similar lines, patients with end-stage chronic obstructive pulmonary disease are not so much limited by hypoxia but by dyspnea from hypercapnia caused by impaired alveolar ventilation (4) . Under these circumstances, respiratory dialysis with ECCO 2 R can increase CO 2 removal, but removing only the CO 2 dissolved in blood cannot permit long offdialysis survival because stopping ECCO 2 R will cause CO 2 concentrations to immediately rise. This therapeutic approach seems doomed to failure unless the CO 2 removed is not only that stored in the blood and interstitium but from the entire body.

Relative to this concept, in this issue of the Journal, Giosa and colleagues (pp. 318-327) report the findings of a physiology study exploring CO 2 kinetics, whole-body stores, and the impact of ventilation and ECCO 2 R on both (5) . Using a porcine model, they measured exhaled CO 2 and _ VO 2 as they altered VE and ECCO 2 R. Armed with this information, they were able to use the respiratory quotient to determine metabolic _ VCO 2 ( _ Vm CO 2 ). Here lies a potential limitation of the work because it was necessary to make certain assumptions for _ Vm CO 2 calculations as the experiment progressed. The animals were subjected to different ventilatory conditions for 48 hours, and the difference between exhaled CO 2 and metabolically produced CO 2 was used to determine changes that had occurred in CO 2 stores. Animals were either hyperventilated or hypoventilated. After 24 hours, some of the hypoventilated animals received ECCO 2 R to supplement alveolar ventilation, and some had ventilation returned to baseline. A key observation of their work was that CO 2 changes occurred in two phases, as follows: a fast phase in which PCO 2 rapidly changed in blood, followed by a slow phase, which was revealed as a failure of measured PCO 2 to reach equilibrium even after 24 or 48 hours. So, how do we interpret these two phases?

Perhaps the simplest data to understand is the fast phase, in which blood and interstitial fluid quickly load or unload their CO 2 stores. Assuming relatively constant metabolism, conventional wisdom accepts that measured PCO 2 reaches a new equilibrium within 45 minutes of ventilatory changes (6) . A quick glance at the kinetics reported by Giosa and colleagues supports this; changes in ventilation (or ECCO 2 R) are followed by a rapid change in PCO 2 that plateaus within 15 minutes and changes little between 15 and 60 minutes. However, by continuing experimental conditions for 24 or 48 hours, the authors showed that PCO 2 steadily increases or decreases at 0.002-0.003 mm Hg/minute depending on whether hypoventilation or hyperventilation is continued.

Importantly, during prolonged hypoventilation, the volume of CO 2 slowly accumulating in the body exceeded the amount present (or stored) in the blood and interstitium. Similarly, during hyperventilation, the volume of expired CO 2 exceeded that which can be explained by the sum of the metabolically produced CO 2 This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rccm.202008-3306ED on September 11, 2020 plus the amount from the blood and interstitium. It is already known that the body stores CO 2 in the tissues, and this study shows that over 80% of the body's CO 2 stores cannot be accounted for by the blood and interstitium, similar to findings reported almost a century ago (7, 8) . This consistency alleviates our anxiety over the authors' assumptions for calculating _ Vm CO 2 . Detailed physiology experiments conducted between the 1930s and 1970s suggest the body stores CO 2 in tissues such as brain, kidney, muscle, fat, and bone (9) (10) (11) . It has been hypothesized that the rate at which these various tissues store CO 2 depends on the speed it enters the tissues and the rate it is converted to bicarbonate; the latter is probably determined by cytosolic concentrations of carbonic anhydrase (10) . Some tissues have very low carbonic anhydrase concentrations, and in certain muscle fibers, it is absent altogether (12) . The question is, how does this validation of CO 2 storage and kinetics affect 21st century clinicians?

First, recognition that the majority of CO 2 is stored in a slow compartment helps us understand why PCO 2 equilibrium is often not achieved in animal studies and clinical trials of ECCO 2 R (13, 14) . Second, as the authors highlighted, it provides a plausible rationale for intermittent CO 2 dialysis in patients with chronic respiratory failure, especially because ECCO 2 R unloads the slow CO 2 store more efficiently than ventilation, presumably because ECCO 2 R can exceed alveolar ventilation. However, this observation might be an artifact of experimental design because the cardiac output was higher in animals receiving hypoventilation, which is likely explained by lower intrathoracic pressures and increased sympathetic tone allowing better venous return to the right ventricle. Third, the presence of a large slow CO 2 tissue compartment enhances our understanding of how nocturnal noninvasive ventilatory support improves daytime PCO 2 values in patients with chronic respiratory failure (15) . Therefore, by refocusing on longer-term kinetics of CO 2 balance, Giosa and colleagues have helped us better understand the therapeutic implications of CO 2 removing maneuvers, such as noninvasive ventilatory support and ECCO 2 R. n

Control of breathing using an extracorporeal membrane lung

The mystery of the pandemic's 'happy hypoxia

Why COVID-19 silent hypoxemia is baffling to physicians

Exercise dyspnea in patients with COPD

Mobilizing carbon dioxide stores: an experimental study

Gas stores of the body and the unsteady state

The source of expired CO( 2 ) in decapitated, eviscerated cats

The source of co( 2 ) expired and the site of its retention

Changes in carbon dioxide stores of rats due to atmospheres low in oxygen or high in carbon dioxide

Serial changes in tissue carbon dioxide content during acute respiratory acidosis

Bone CO 2 -titration curves in acute hypercapnia obtained with a modified titration technique

Carbonic anhydrase in skeletal and cardiac muscle from rabbit and rat

Respiratory dialysis-A novel low bicarbonate dialysate to provide extracorporeal CO 2 removal

A novel extracorporeal CO( 2 ) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD

Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study